Vertex Spikes On Positive Phase 2 Trial Results For VX-548 I

Shares of Vertex Pharmaceuticals Inc. (VRTX) are progressing more than 9 percent on Wednesday morning trade after reporting positive results for its phase 2 study of VX-548 for the painful diabetic peripheral neuropathy.

Related Keywords

, Vertex Pharmaceuticals Inc , Vertex Pharmaceuticals , Diabetes , Vertex Pharma , Stock Alert , Neuropathy , Vx 548 ,